The UK Primary Immunodeficiency Network (UKPIN) has produced advice for healthcare professionals looking after patients with Immunodeficiency regarding COVID-19.
Key medicines-related issues
- It is recommended that Immunology services should still support the on-going provision of immunoglobulin replacement therapy for patients with immunodeficiency unless they are advised by their trust or national body that this is no longer possible.
- Day unit attendance may be minimised in the following ways: starting antibiotic prophylaxis (to replace immunoglobulin therapy); changes to immunoglobulin dosing (by increasing interval); consideration of home therapy.
The document includes a table on risk stratification of patients with primary immunodeficiencies and secondary antibody deficiencies; the table details how various classes of medications used in these patient groups can affect their risk of harm from COVID-19.
Also provides a document on prioritisation of services if staffing/facilities have reduced capacity, which includes information on managing medicines such as IV immunoglobulin.